drug
(sacubitril + valsartan)
Marketedupdated 6mo agoby Novugen Pharma (Malaysia) Sdn Bhd
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Patent cliff
source: FDA Orange Bookfirst barrier falls
May 8, 2027
169 days
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (24)
- May 9, 2036method-of-use (U-3170)US 11058667
- May 9, 2036method-of-use (U-3170)US 11058667
- May 9, 2036method-of-use (U-3170)US 11058667
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 11135192
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9517226
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Aug 22, 2033method-of-use (U-3084)US 9937143
- Nov 27, 2027patentUS 8877938*PED1.0y
- Nov 27, 2027patentUS 8877938*PED1.0y
- Nov 27, 2027patentUS 8877938*PED1.0y
- May 27, 2027compositionUS 8877938188d
- May 27, 2027compositionUS 8877938188d
- May 27, 2027compositionUS 8877938188d
- May 8, 2027patentUS 9388134*PED169d
- May 8, 2027patentUS 9388134*PED169d
- May 8, 2027patentUS 9388134*PED169d
- Nov 8, 2026method-of-use (U-1723)US 9388134
- Nov 8, 2026method-of-use (U-1723)US 9388134
- Nov 8, 2026method-of-use (U-1723)US 9388134
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 6h ago
Found something off?
comments(0)
5-min edit window · permanent after that